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Abstract
Mycoplasma hominis is an opportunistic human mycoplasma species that can be either commensal or pathogenic. Its detection by culture
is considered to comprise the reference technique. Previously reported PCR techniques target the 16S rRNA or the gap gene, although
sequence variations among clinical isolates may lead to variations in clinical sensitivity. The present study aimed to develop a speciﬁc
TaqMan quantitative real-time PCR assay, targeting a gene conserved in all M. hominis isolates, and to compare it with quantitative
culture. With the knowledge of the M. hominis PG21 genome sequence, the yidC gene, encoding a membrane protein translocase, was
chosen as target. Its intraspecies heterogeneity was checked at the nucleotide level using 31 reference or clinical strains. The limit of
detection, the analytical speciﬁcity and the reproducibility of the assay were assessed. Moreover, PCR and culture results were
compared using 153 urogenital specimens. The limit of detection was seven copies/lL. The analytical speciﬁcity was 100%, with good
inter- and intra-assay reproducibility. Among the 153 urogenital specimens, the yidC PCR and culture allowed detection of 55 and 45
M. hominis-positive samples, respectively. Comparison of the bacterial load among the 45 specimens found to be M. hominis-positive by
both techniques revealed a statistically signiﬁcant association between the quantitative results obtained. In conclusion, we developed a
speciﬁc, sensitive and reproducible real-time PCR to detect all M. hominis clinical isolates. This PCR was shown to have higher sensitivity
than culture, although both methods were correlated for quantiﬁcation of M. hominis loads in urogenital specimens.
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Introduction
Mycoplasma hominis is an opportunistic human mycoplasma
species that resides, as a commensal, in the lower urogenital
tract. It can also be a causal agent in pelvic inﬂammatory disease
and infections during pregnancy, and it has been associated
with bacterial vaginosis [1]. In newborns, it can cause pneumo-
nia, meningitis or abscesses [2]. It has also been involved in
extragenital infections, especially in immunocompromised
patients [1]. Direct detection techniques are the only methods
adequate for genital mycoplasmas. Although culture is consid-
ered to be the reference technique for the detection of
M. hominis, it requires specialized media and expertise and
does not yield results before 2–5 days [3]. Most PCR tech-
niques detecting M. hominis target the 16S rRNA gene or the
16S-23S intergenic spacer region by conventional or real-time
assays [4–9]. However, minor sequence variations were
observed in the 16S rRNA gene sequences [10] and may lead
to a lower clinical sensitivity of these techniques. A quantitative
real-time PCR using hybridization probes and targeting the
glyceraldehyde-3-phosphate dehydrogenase gene (gap) was
reported [11]. Variation in the gap gene was also described and
the extent of variation was found to be larger than in the 16S
rRNA gene [11,12]. Recently, a real-time PCR assay targeting
the fstY gene of M. hominis was reported, although the intra-
species heterogeneity within this gene was not assessed [13].
The present study aimed to develop a TaqMan quantita-
tive real-time PCR assay, speciﬁc for the M. hominis species,
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targeting a gene conserved in all M. hominis isolates. The yidC
gene was selected as a target, and the speciﬁcity, limit of
detection and reproducibility of the assay were evaluated. In
addition, the M. hominis detection by quantitative culture and
by our real-time PCR assay was compared using 153 clinical
urogenital specimens.
Materials and Methods
Organisms and specimens
The organisms used in the present study are listed in Table 1.
Among mollicutes, all human species with a potential patho-
genic role and some human and animal species phylogenetically
close to M. hominis were tested. All isolates of mycoplasma or
ureaplasma species were grown in Hayﬂick modiﬁed medium
or Shepard medium, according to the species [3].
A total of 153 urogenital samples, collected between
September 2007 and March 2008 and conserved frozen in
2 mL of 2SP transport medium [3], were retrospectively
selected from the Department of Bacteriology, University
Hospital of Bordeaux (France). They included 110 cervico-
vaginal swabs, 20 peritoneal liquids, 15 urethral swabs, ﬁve
anal swabs, two endometrial specimens and one of the fallo-
pian tube. Among them, 45 were positive by a quantitative
culture technique in Hayﬂick modiﬁed broth medium supple-
mented with arginine [3]. The bacterial load was measured
in colour-changing units (CCU) per mL. DNA was extracted
from 190 lL of clinical specimens or bacterial cultures sup-
plemented with 10 lL of internal control (see below) using
the MagNA Pure LC DNA isolation kit I (Roche, Meylan,
France) in accordance with the manufacturer’s instructions.
Taqman assay
The M. hominis PG21 genome [14] was compared with other
available sequenced mycoplasma genomes using a bidirec-
tional best hit method from the multiproteome differential
query tool of the MolliGen 2.0 database (http://www.cbib.
u-bordeaux2.fr/outils/molligen/home.php). Primers and a
probe were designed for a fully-conserved gene fragment of
the yidC gene (MHO_0010, Genbank FP236530) using the
PRIMER EXPRESS software (Applied Biosystems, Foster City, CA,
USA), and their speciﬁcity was checked by BLAST analysis.
Our assay, targeting a 94-bp fragment of the M. hominis
yidC gene, was performed using primers MHyidCfwd (5¢-TC
ACTAAACCGGGTATTTTCTAACAA-3¢, nucleotides (nt)
1642–1667) and MHyidCrev (5¢-TTGGCATATATTGCGA
TAGTGCTT-3¢, nt 1735–1712), and the TaqMan probe
MHyidC (5¢-FAM-CTACCAATAATTTTAATATCTGTCGG
TATG-BHQ1-3¢, nt 1681–1710). To monitor the efﬁciency
of DNA extraction and PCR inhibition, a DNA extraction
and inhibition internal control (IC) labelled with the Cy5 dye
was used (Diagenode, Lie`ge, Belgium). The PCR reaction
mixture consisted of 10 lL of 2· LightCycler 480 Probes
Master (Roche), 0.6 lL of each primer (10 lM), 0.8 lL of
the probe (5 lM), 2 lL of IC primers/probe (Diagenode)
and 1 lL of template DNA including the extracted IC DNA.
Ampliﬁcations were performed using a LightCycler 480 ther-
mocycler (Roche) under the conditions: initial denaturation
at 95C for 10 min, followed by 45 cycles of 10 s at 95C
and 1 min at 60C. Each sample was tested in duplicate and
negative results were validated if the internal control gave a
ﬂuorescent signal.
Speciﬁcity, limit of detection and reproducibility
To determine the analytical speciﬁcity of the assays, DNA
extracts from 11 mycoplasma and two ureaplasma species
TABLE 1. Microorganisms used to assess the speciﬁcity of
the real-time PCR assay
Mycoplasma and ureaplasma strains
Mycoplasma agalactiae
Mycoplasma amphoriforme
Mycoplasma arginini
Mycoplasma arthritidis
Mycoplasma fermentans
Mycoplasma genitalium
Mycoplasma orale
Mycoplasma penetrans
Mycoplasma pneumoniae
Mycoplasma pulmonis
Mycoplasma salivarium
Ureaplasma urealyticum
Ureaplasma parvum
Other bacterial or fungal strains
Acinetobacter baumannii
Candida albicans
Chlamydia trachomatis
Clostridium perfringens
Corynebacterium striatum
Enterobacter aerogenes
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Gardnerella vaginalis
Haemophilus inﬂuenzae
Haemophilus parainﬂuenzae
Klebsiella oxytoca
Lactobacillus acidophilus
Moraxella catarrhalis
Morganella morganii
Neisseria perﬂava
Neisseria gonorrhoeae
Prevotella bivia
Pseudomonas aeruginosa
Pseudomonas putida
Serratia marcescens
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus xylosus
Streptococcus agalactiae
Streptococcus anginosus
Streptococcus constellatus
Streptococcus bovis
Streptococcus oralis
Streptococcus pneumoniae
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and 32 bacterial or fungal species from the urogenital tract
(Table 1) were tested.
To evaluate the detection limit of the assay, the 732-nt
C-terminal fragment of the yidC gene of the PG21 strain was
ampliﬁed with the MHO_0010fwd (5¢-ACAAAGAATAT
TGAGCACAAGGAC-3¢) and MHO_0010rev (5¢- CGAAAT
TAAGGTGTGGCGTTT-3¢) primers. The ampliﬁed product
was then puriﬁed using the Wizard PCR Preps DNA puriﬁ-
cation system (Promega, Charbonnie`res-les-Bains, France)
and subsequently cloned into the plasmid vector pGEM-T
Easy (Promega) in accordance with the manufacturer’s
instructions. Escherichia coli was transformed with the result-
ing calibration plasmid pCMh which was puriﬁed from the
E. coli transformants using the Wizard Plus SV Minipreps
DNA Puriﬁcation System (Promega). The purity and concen-
tration of the plasmid DNA were determined by optical den-
sity measurements (NanoDrop 1000; NanoDrop,
Wilmington, DE, USA). Ten-fold serial dilutions of pCMh
from 7 · 108 to 0.7 copies/lL were used to generate stan-
dard curves from the threshold cycles (Ct). To determine
the limit of detection of our PCR assay, ten-fold serially
diluted pCMh was ampliﬁed in duplicate. Those dilutions
were also spiked with IC DNA and ampliﬁcations carried
out in the presence of IC primers and a probe to assess pos-
sible competition.
The concentration of the M. hominis DNA in clinical speci-
mens was calculated as copy number per lL using the pCMh
standard curve. In case of qualitative discordance between
PCR and culture results, both techniques were performed
again using a new frozen specimen aliquot.
To assess the reproducibility of the assay, the intra- and
inter-assay variations were measured with respect to Ct and
concentration. To determine the intra-assay variation, three
standard dilution series from 7–7 · 107 pCMh copies were
tested in one run. Nine standard curves were evaluated in
different PCR runs for the determination of the inter-assay
variation. Coefﬁcients of variation were calculated.
Sequencing analysis
The 732-nt C-terminal fragment of the yidC gene from three ref-
erence M. hominis strains, PG21 (ATCC 23114), H34 (ATCC
15056) and M132 (ATCC 43521) and 28 M. hominis clinical iso-
lates from the collection of the Department of Bacteriology,
University Hospital of Bordeaux (France), were sequenced
using the MHO_0010fwd and MHO_0010rev primers.
Statistical analysis
Comparison between culture and qualitative PCR results was
made using McNemar’s test. The Kruskall–Wallis test was
used to compare quantitative PCR results according to three
categories of quantitative culture results (i.e. <104, 104 and
>104 CCU/mL).
Results and Discussion
Choice of the gene target
Because our laboratory sequenced the whole genome of the
M. hominis PG21 reference strain [14], we compared it with
other available sequenced mycoplasma genomes using the
MolliGen 2.0 database to identify a gene speciﬁc to the
M. hominis species. We selected several M. hominis genes that
were speciﬁc for the M. hominis species in silico. Primers
were designed for each gene. We checked for absence of
ampliﬁcation with a set of non M. hominis strains, for the
presence of ampliﬁcation with a set of M. hominis strains, and
subsequently searched for intraspecies heterogeneity (data
not shown). The yidC gene, which encodes a putative inner
membrane protein translocase component, YidC, was chosen
for further investigation.
To check for intraspecies heterogeneity at the nucleotide
level, the C-terminal 732-nt fragments of the yidC gene from
three M. hominis reference strains and 28 M. hominis clinical
isolates were sequenced and aligned. Only seven of 732 nt
varied among the 31 strains studied, and were found to be
outside of the sequences of primers and probe used for
ampliﬁcation with the developed Taqman assay.
Sensitivity and speciﬁcity
The assay with the yidC probe and primer set selected
was robust and sensitive. The mean efﬁciency of our PCR
reaction was 1.93, oscillating between 1.9 and 2.0 when inde-
pendent dilution series were analyzed. Ideally, the efﬁciency
is equal to 2. The limit of detection of our assay was seven
copies/lL. This limit of detection was unchanged in the
presence of the IC. This analytical limit of detection was con-
sistent with the sensitivities previously reported for real-time
PCR techniques detecting M. hominis [11,13]. However,
as previously shown for Mycoplasma pneumoniae [15], the
analytical sensitivity may not predict the ability to detect
the bacterial target in clinical specimens. In a highly variable
species such as M. hominis [16], the PCR target conservation
at the nucleotide level is essential for providing a high clinical
sensitivity. Thus, we could speculate that our PCR assay may
have a higher clinical sensitivity than the previously reported
PCRs.
The assay was speciﬁc for M. hominis because no ampliﬁca-
tion was observed with various other mycoplasmal or with
non-mycoplasmal species, although the IC was properly
ampliﬁed. The coefﬁcients of variation of the Ct were in the
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range 0.173–2.199% for intra-assay reproducibility and in the
range 0.230–2.042% for inter-assay reproducibility, conﬁrm-
ing the robustness of our real-time PCR (Table 2).
Analysis of clinical samples and comparison with culture
Results of our real-time PCR assay were compared with
those of the culture technique using 153 urogenital samples.
No ampliﬁcation was obtained for 98 samples among the
108 culture-negative specimens. No extraction failure or
ampliﬁcation inhibition was detected. A positive signal was
detected for 45 of the 45 culture-positive samples, whereas
ten culture-negative samples (seven cervico-vaginal swab and
three urethral swab specimens) were found to be positive by
our PCR assay. These ten discordant results were all con-
ﬁrmed by performing culture and real-time PCR again, using
a new frozen sample aliquot. Thus, the PCR assay had a sta-
tistically signiﬁcantly higher clinical sensitivity than the culture
technique (p 0.004) with the 153 different clinical samples
tested. This is in contrast to the results reported for the
real-time PCR targeting the gap gene [11], for which there
was 100% agreement between culture and real-time PCR,
although it is consistent with the results reported for con-
ventional PCR techniques [17–19]. Indeed, PCR has an
advantage over culture because it can also detect organisms
with an altered viability.
A comparison of the bacterial load measured by the yidC
quantitative PCR or by quantitative culture was performed
with the 45 specimens positive with both techniques. Speci-
mens with a bacterial load <104 CCU/mL by culture (n = 10)
had a median M. hominis DNA load of 300 copies/lL by PCR
(range 10–700) (Fig. 1). The 14 specimens with a bacterial
load of 104 CCU/mL by culture had a median load of
5000 copies/lL (range 500–30 000) by PCR, whereas the 21
specimens with a load of >104 CCU/mL had a median load
of 2.105 copies/lL (range 2.102–2.106). A statistically signiﬁ-
cant association was found between the bacterial load mea-
sured by quantitative PCR and the bacterial load measured
by quantitative culture (p <0.001). Indeed, the PCR load
results increased with increasing culture load results.
The M. hominis load of 104 CCU/mL is a crucial threshold
concentration in clinical specimens because it is a signiﬁcant
criterion for urogenital infections in women [20]. Because
our quantitative PCR results are correlated with those of
the quantitative culture method, a DNA load of 5.103 cop-
ies/lL could be proposed as a signiﬁcant threshold using our
quantitative PCR. Nevertheless, this threshold still remains
to be accurately determined based on a comparison of a
higher number of M. hominis-positive urogenital specimens.
In conclusion, we developed a speciﬁc, sensitive, repro-
ducible and quantitative real-time PCR assay for the detec-
tion of M. hominis. This quantitative PCR was shown to have
a higher clinical sensitivity than the reference culture tech-
nique. Both methods were correlated with respect to the
quantiﬁcation of M. hominis loads in urogenital specimens.
Because the yidC gene target is conserved at the nucleotide
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FIG. 1. Mycoplasma hominis DNA load deter-
mined with the yidC quantitative real-time
PCR in urogenital specimens positive by quan-
titative culture. The median DNA load for
each culture group [<104, 104 or >104 col-
our-changing units (CCU)/mL] is indicated by
a horizontal line.
TABLE 2. Inter-assay and intra-assay reproducibility
Intra-assay reproducibility Inter-assay
reproducibility
pCMh copy
number/lLa
Mean
Crossing-point
(Ct ± SD)b CV (%)
Mean
Crossing-point
(Ct ± SD)b CV (%)
7 · 108 12.35 ± 0.27 2.199 12.55 ± 0.1 0.829
7 · 107 16.043 ± 0.13 0.795 16.07 ± 0.04 0.230
7 · 106 19.08 ± 0.21 1.108 19.35 ± 0.32 1.660
7 · 105 22.33 ± 0.09 0.359 22.57 ± 0.27 1.194
7 · 104 25.87 ± 0.08 0.293 26.17 ± 0.34 1.304
7 · 103 28.7 ± 0.05 0.173 29.32 ± 0.55 1.869
7 · 102 32.26 ± 0.22 0.668 32.82 ± 0.38 1.156
7 · 101 35.49 ± 0.37 1.042 35.77 ± 0.53 1.472
7 · 100 37.07 ± 0.3 0.809 38.46 ± 0.79 2.042
aCopy numbers of pCMh were calculated from spectrophotometrically quanti-
ﬁed DNAs as described in the Materials and methods.
bMean (SD) crossing-point values were calculated from triplicates of each plas-
mid concentration tested in one PCR assay.
CV, coefﬁcient of variation.
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level among M. hominis isolates, this PCR assay may have a
higher clinical sensitivity than ampliﬁcation techniques previ-
ously described. Furthermore, it may also be a useful tool
for the detection of M. hominis in specimens for which the
culture lacks sensitivity (e.g. amniotic ﬂuids, pelvic inﬂamma-
tory disease and extra-genital specimens) [2].
Transparency Declaration
The authors have no conﬂicts of interest to declare.
References
1. Waites K, Talkington D. New developments in human diseases due
to mycoplasmas. In: Blanchard A, Browning GF, eds, Mycoplasmas
molecular biology pathogenicity and strategies for control. Wymondham:
Horizon Bioscience, 2005; 289–354.
2. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as
neonatal pathogens. Clin Microbiol Rev 2005; 18: 757–789.
3. Waites KB, Be´be´ar CM, Roberston JA, Talkington DF, Kenny GE,
eds. Cumitech 34, Laboratory diagnosis of mycoplasmal infections. Wash-
ington, DC: ASM Press, 2001.
4. Blanchard A, Yanez A, Dybvig K, Watson HL, Grifﬁths G, Cassell
GH. Evaluation of intraspecies genetic variation within the 16S rRNA
gene of Mycoplasma hominis and detection by polymerase chain reac-
tion. J Clin Microbiol 1993; 31: 1358–1361.
5. Dussurget O, Roulland-Dussoix D. Rapid, sensitive PCR-based detec-
tion of mycoplasmas in simulated samples of animal sera. Appl Environ
Microbiol 1994; 60: 953–959.
6. Grau O, Kovacic R, Griffais R, Launay V, Montagnier L. Development
of PCR-based assays for the detection of two human mollicute species,
Mycoplasma penetrans and M. hominis. Mol Cell Probes 1994; 8: 139–147.
7. Wang H, Kong F, Jelfs P, James G, Gilbert GL. Simultaneous detec-
tion and identiﬁcation of common cell culture contaminant and path-
ogenic mollicutes strains by reverse line blot hybridization. Appl
Environ Microbiol 2004; 70: 1483–1486.
8. Yoshida T, Maeda S, Deguchi T, Miyazawa T, Ishiko H. Rapid
detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma
parvum, and Ureaplasma urealyticum organisms in genitourinary sam-
ples by PCR-microtiter plate hybridization assay. J Clin Microbiol 2003;
41: 1850–1855.
9. Zariffard MR, Saifuddin M, Sha BE, Spear GT. Detection of bacterial
vaginosis-related organisms by real-time PCR for Lactobacilli, Gardne-
rella vaginalis and Mycoplasma hominis. FEMS Immunol Med Microbiol
2002; 34: 277–281.
10. Mygind T, Birkelund S, Christiansen G. DNA sequencing reveals lim-
ited heterogeneity in the 16S rRNA gene from the rrnB operon
among ﬁve Mycoplasma hominis isolates. Int J Syst Bacteriol 1998; 48:
1067–1071.
11. Baczynska A, Svenstrup HF, Fedder J, Birkelund S, Christiansen G.
Development of real-time PCR for detection of Mycoplasma hominis.
BMC Microbiol 2004; 4: 35.
12. Mygind T, Zeuthen Sogaard I, Melkova R, Boesen T, Birkelund S,
Christiansen G. Cloning, sequencing and variability analysis of the gap
gene from Mycoplasma hominis. FEMS Microbiol Lett 2000; 183: 15–21.
13. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular
quantiﬁcation of Gardnerella vaginalis and Atopobium vaginae loads to
predict bacterial vaginosis. Clin Infect Dis 2008; 47: 33–43.
14. Pereyre S, Sirand-Pugnet P, Beven L et al. Life on arginine for Myco-
plasma hominis: clues from its minimal genome and comparison with
other human urogenital mycoplasmas. PLoS Genet 2009; 5: e1000677.
15. Touati A, Benard A, Ben Hassen A, Be´be´ar CM, Pereyre S. Evaluation
of ﬁve commercial real-time PCR assays for the detection of Myco-
plasma pneumoniae in respiratory tract specimens. J Clin Microbiol
2009; 47: 2269–2271.
16. Ladefoged SA, Christiansen G. Physical and genetic mapping of the
genomes of ﬁve Mycoplasma hominis strains by pulsed-ﬁeld gel elec-
trophoresis. J Bacteriol 1992; 174: 2199–2207.
17. Abele-Horn M, Wolff C, Dressel P et al. Polymerase chain reaction
versus culture for detection of Ureaplasma urealyticum and Myco-
plasma hominis in the urogenital tract of adults and the respiratory
tract of newborns. Eur J Clin Microbiol Infect Dis 1996; 15: 595–598.
18. Luki N, Lebel P, Boucher M, Doray B, Turgeon J, Brousseau R. Com-
parison of polymerase chain reaction assay with culture for detection
of genital mycoplasmas in perinatal infections. Eur J Clin Microbiol Infect
Dis 1998; 17: 255–263.
19. Stellrecht KA, Woron AM, Mishrik NG, Venezia RA. Comparison of
multiplex PCR assay with culture for detection of genital mycoplas-
mas. J Clin Microbiol 2004; 42: 1528–1533.
20. Be´be´ar C, Pereyre S, Be´be´ar CM. Mycoplasma spp. In: Gillespie SH,
Hawkey PM, eds, Principles and practice of clinical bacteriology, 2nd edn.
Chichester: Wiley and Sons, 2006: 305–315.
CMI Fe´randon et al. Mycoplasma hominis quantitative real-time PCR 159
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 155–159
